[1
]
From the Centre for Imaging Sciences, Institute of Population Health (W.J.Z., P.L.H.C.,
J.H.N., G.J.M.P.), and Biomedical Imaging Institute (W.J.Z., P.L.H.C., J.H.N., G.J.M.P.),
University of Manchester, Oxford Rd, Stopford Building, Room G522, Manchester M13
9PT3, England; Respiratory & Inflammation Therapy Area, Clinical Development, AstraZeneca,
Mölndal, Sweden (E.B., L.H.N.); Personalised Healthcare and Biomarkers, AstraZeneca,
Alderley Park, Macclesfield, England (S.S.Y., Y.Z.L.); Medicines Evaluation Unit,
University of Manchester, University Hospital of South Manchester Foundation Trust,
Manchester, England (D.S.); and Bioxydyn, Manchester, England (J.H.N., G.J.M.P.).